Figure 2.

Markers of microbial translocation (A and B), inflammation (C), and intestinal damage (D) in patients who developed BSI (n = 8) after Clostridioides difficile infection (CDI), in comparison with subjects not who did not develop BSI (n = 37). Horizontal lines and whiskers represent median and the 25th and 75th percentile values, respectively. *P < .01; ^**P < .001. Abbreviations: EndoCab IgM, antiendotoxin core antibody IgM; I-FABP, intestinal fatty acid binding protein; LBP, lipopolysaccharide-binding protein; T0, at the beginning of CDI-specific therapy; T1, at the end of CDI-specific therapy.